Supplier controls may get closer review under possible QSIT change
This article was originally published in The Silver Sheet
FDA may change its Quality System Inspection Technique (QSIT) to place more emphasis on the auditing of supplier controls, an agency official says. "Purchasing controls is something that right now is very, very timely," Jan Welch, a consumer safety officer in CDRH's Office of Compliance, said at a Global Harmonization Task Force (GHTF) conference Oct. 4 in Washington, D.C. "FDA is giving consideration to revising QSIT, thinking about where purchasing controls might have a more elevated, heightened awareness within QSIT. That's a very, very good thing." Manufacturer problems with outsourcing and supplier controls also is emerging as a hot-button issue for GHTF, which has tasked its Study Group 3 with creating a purchasing control guidance expected to be released in draft form this fall
You may also be interested in...
Pharma manufacturing is operating well below normal levels in India, disrupted by labor absenteeism and supply chain issues amid the ongoing lock-down in the country, though the government is actively engaged in addressing bottlenecks. A speedy recovery is vital not just for domestic supplies.
Moderna is pursuing a single-antigen strategy even though some of its mRNA vaccines have included multiple antigens; the SARS-CoV-2 spike protein likely provides the best antigen for developing immunity against the virus.
Latest warnings also include second and third businesses in US cannabidiol and hemp sector found making unlawful claims for treating and preventing COVID-19. Four of five firms warned apparently responded by removing violative claims from websites and social media posts.